XML 46 R36.htm IDEA: XBRL DOCUMENT v3.25.3
The Company (Details)
$ in Thousands, € in Millions
1 Months Ended 9 Months Ended 12 Months Ended
Oct. 06, 2025
USD ($)
shares
Apr. 07, 2025
USD ($)
Apr. 07, 2025
EUR (€)
Sep. 30, 2025
USD ($)
Sep. 30, 2025
USD ($)
Sep. 30, 2024
USD ($)
Dec. 31, 2022
USD ($)
Mar. 27, 2025
USD ($)
Mar. 27, 2025
EUR (€)
Dec. 31, 2024
USD ($)
Subsidiary or Equity Method Investee [Line Items]                    
Cash and cash equivalents       $ 69,837 $ 69,837         $ 32,456
Capital increases, net of transaction costs   $ 125,500 € 116.3   $ 116,936 $ 0        
Issuance or sale of equity, maximum potential amount               $ 181,400 € 168.2  
Private investment in Public Equity                    
Subsidiary or Equity Method Investee [Line Items]                    
Proceeds from issuance of common stock             $ 194,000      
American depositary share | Maximum                    
Subsidiary or Equity Method Investee [Line Items]                    
Sale of stock, at-the-market equity program, aggregate offering price limit       $ 150,000            
American depositary share | Subsequent event                    
Subsidiary or Equity Method Investee [Line Items]                    
Proceeds from issuance of common stock $ 30,000                  
Stock issued during period (in shares) | shares 2,307,692                  
Common stock | Subsequent event                    
Subsidiary or Equity Method Investee [Line Items]                    
Stock issued during period (in shares) | shares 11,538,460